Fidelity Disruptive Medicine ETF

FMED
ETF Ticker

+16.08%

+20.98%

NASDAQ

Equity

Global

Thematic

The Fidelity Disruptive Medicine ETF, FMED_US, is an actively managed strategy providing exposure to Global, Thematic Equity. It is listed on the NASDAQ and has assets under management of $51.4m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Apr 16, 2020. It has a net expense ratio of 50bps. (All data in USD as of Oct 9, 2026 unless stated.)

The investment framework informing the actively managed Fidelity Disruptive Medicine ETF governs a global, thematic equity portfolio that normally invests ≥80% of assets in securities of companies advancing disruptive medicine, including areas such as genomics, gene therapy, immunotherapy, robotic surgery, medical devices/equipment, rare-disease platforms, technology-enabled health-care services, and consumer wellness. Research combines fundamental issuer analysis—business model durability, competitive positioning, financial condition—with quantitative portfolio construction to assemble a risk-aware set of growth and value names across market caps and developed/emerging markets, while the strategy typically concentrates in health-care industries. Position sizing reflects conviction, liquidity, and correlation considerations; diversification is managed across subsectors and innovation modalities. Rebalancing and trims crystallize when thesis milestones miss, regulatory/clinical risk alters probability-weighted outcomes, fundamentals or valuations deteriorate, or higher-ranked opportunities emerge, while maintaining theme purity and investability.

ETF Details

Key Facts

Issuer:
Fidelity
AUM:
$51.4m (as of Aug 31, 2026)
Net Expense Ratio:
50 bps
Inception Date:
Apr 16, 2020
Index:
Actively managed strategy
Dividend Frequency:
N/A

Trading

Ticker:
FMED
Exchange:
NASDAQ
ISIN:
US3160921470
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
Global
Theme:
Thematic
Economic Development:
Global Markets
1 Year Volatility:
22.53%
3 Year Volatility:
19.93%
5 Year Volatility:
N/A

Performance

TTM Dividend Yield:
0.00% (verify with issuer)
1 Month Performance:
0.41%
3 Month Performance:
4.30%
6 Month Performance:
24.80%
1 Year Performance:
20.98%
3 Year Performance:
44.10%
5 Year Performance:
N/A
Investment Proposition

Fidelity Disruptive Medicine ETF (FMED) presents concentrated exposure to companies advancing next-generation healthcare—genomic medicine, engineered biologics, precision diagnostics, robotic and minimally invasive procedures, and digital health tools. The actively managed approach seeks capital growth by underwriting clinical and commercialization inflection points, assessing intellectual property, reimbursement pathways, and manufacturing scalability while balancing earlier-stage innovators with established medtech and tools providers. Factor tilts often align with growth and quality, though clinical catalysts can introduce idiosyncratic volatility and longer duration. The strategy is sensitive to regulatory outcomes, trial readouts, and funding conditions, yet can benefit in regimes prioritizing productivity in care delivery and innovation in drug/device pipelines. Portfolio roles include thematic satellite for healthcare innovation, a diversification sleeve within health care to complement traditional pharma/biotech exposure, and a targeted alpha sleeve focused on medical technology adoption. Suitable investors include research-driven allocators comfortable with milestone risk and equity managers building specialized healthcare sleeves. Environments with supportive capital markets and steady reimbursement frameworks are constructive; broad risk-off or policy uncertainty can challenge. Key risk: binary clinical and approval outcomes can materially impact holdings, requiring disciplined position sizing and risk controls.

ETF Analytics

Fund Discovery

4 Suggestions